Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia by Line of Therapy in the United States (US) from a Commercial Perspective

被引：0
|
作者：
Atallah, Ehab [1 ]
Maegawa, Rodrigo [2 ]
Latremouille-Viau, Dominick [3 ]
Rossi, Carmine [3 ]
Guerin, Annie [3 ]
Patwardhan, Pallavi [2 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
CML; chronic myeloid leukemia; chronic phase; tyrosine kinase inhibitors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-311
引用
收藏
页码：S333 / S333
页数：1
相关论文
共 50 条
  • [1] Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy
    Atallah, Ehab L.
    Maegawa, Rodrigo
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Guerin, Annie
    Patwardhan, Pallavi
    BLOOD, 2020, 136
  • [2] HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UNITED STATES
    Cameron, A.
    Barrett, M.
    Malik, A.
    Woodford, C.
    Alpert, N.
    Vuong, V.
    Boers, E.
    Kaye, L.
    Sterling, K. L.
    VALUE IN HEALTH, 2022, 25 (12) : S176 - S176
  • [3] Evaluation of Healthcare Resource Utilization and Costs Among Patients with Chronic Myeloid Leukemia after Disease Progression
    Jabbour, Elias
    Lin, Jay
    Siegartel, Lisa R.
    Lingohr-Smith, Melissa
    Menges, Brandy
    Makenbaeva, Dinara
    BLOOD, 2016, 128 (22)
  • [4] Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
    Atallah, Ehab L.
    Maegawa, Rodrigo
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Guerin, Annie
    Wu, Eric Q.
    Patwardhan, Pallavi
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2022, 9 (02): : 19 - 29
  • [5] Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States
    Seiter, Karen
    Latremouille-Viau, Dominick
    Guerin, Annie
    Ndife, Briana
    Habucky, Karen
    Joseph, George J.
    Pivneva, Irina
    Gagnon-Sanschagrin, Patrick
    Tang, Derek H.
    BLOOD, 2017, 130
  • [6] Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States
    Muffly, Lori
    Young, Christopher
    Feng, Qi
    Nimke, David
    Pandya, Bhavik J. J.
    LEUKEMIA & LYMPHOMA, 2023, 64 (11) : 1832 - 1839
  • [7] Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
    Wu, Eric Q.
    Johnson, Scott
    Beaulieu, Nicolas
    Arana, Mateo
    Bollu, Vamsi
    Guo, Amy
    Coombs, John
    Feng, Weiwei
    Cortes, Jorge
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) : 61 - 69
  • [8] Annual Healthcare Resource Utilization and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia
    Tabah, Ashley
    Knoth, Russell L.
    Huggar, David
    Copher, Ronda
    Cao, Zhun
    Lipkin, Craig
    Leblanc, Thomas W.
    BLOOD, 2020, 136
  • [9] ANNUAL HEALTHCARE RESOURCE UTILIZATION AND COSTS IN US PATIENTS DIAGNOSED WITH RELAPSED ACUTE MYELOID LEUKEMIA
    Huggar, D.
    Knoth, R. L.
    Cao, Z.
    Lipkin, C.
    Copher, R.
    LeBlanc, T. W.
    VALUE IN HEALTH, 2021, 24 : S28 - S28
  • [10] Healthcare Resource Utilization and Costs Associated With Eosinophilic Esophagitis Among Commercially Insured Patients in the United States
    Xia, Qian
    Tencer, Tom
    Jobson, Greeta
    Qian, Ellen
    Dellon, Evan S.
    Biswas, Mousumi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (11): : 2326 - 2330
12345